Literature DB >> 33804404

Plasma Proteomic Profiling in Hypertrophic Cardiomyopathy Patients before and after Surgical Myectomy Reveals Post-Procedural Reduction in Systemic Inflammation.

Amy Larson1, Towia A Libermann2, Heather Bowditch1, Gaurav Das1, Nikolaos Diakos3, Gordon S Huggins1,3, Hassan Rastegar3,4, Frederick Y Chen3, Ethan J Rowin3,4, Martin S Maron3,4, Michael T Chin1,3,4.   

Abstract

Left Ventricular Outflow Tract (LVOT) obstruction occurs in approximately 70% of Hypertrophic Cardiomyopathy (HCM) patients and currently requires imaging or invasive testing for diagnosis, sometimes in conjunction with provocative physiological or pharmaceutical stimuli. To identify potential biomarkers of LVOT obstruction, we performed proteomics profiling of 1305 plasma proteins in 12 HCM patients with documented LVOT obstruction, referred for surgical myectomy. Plasma was collected at the surgical preoperative visit, approximately one month prior to surgery and then at the post-surgical visit, approximately 3 months later. Proteomic profiles were generated using the aptamer-based SOMAscan assay. Principal Component Analysis using the highest statistically significant proteins separated all preoperative samples from all postoperative samples. Further analysis revealed a set of 25 proteins that distinguished the preoperative and postoperative states with a paired t-test p-value of <0.01. Ingenuity Pathway analysis facilitated the generation of protein interaction networks and the elucidation of key upstream regulators of differentially expressed proteins, such as interferon-γ, TGF-β1, and TNF. Biological pathways affected by surgery included organ inflammation, migration, and motility of leukocytes, fibrosis, vasculogenesis, angiogenesis, acute coronary events, endothelial proliferation, eicosanoid metabolism, calcium flux, apoptosis, and morphology of the cardiovascular system. Our results indicate that surgical relief of dynamic outflow tract obstruction in HCM patients is associated with unique alterations in plasma proteomic profiles that likely reflect improvement in organ inflammation and physiological function.

Entities:  

Keywords:  aptamer; cardiovascular disease; hypertrophic cardiomyopathy; myectomy surgery; proteomics

Mesh:

Substances:

Year:  2021        PMID: 33804404      PMCID: PMC7957543          DOI: 10.3390/ijms22052474

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  28 in total

Review 1.  NAMPT: A pleiotropic modulator of monocytes and macrophages.

Authors:  Cristina Travelli; Giorgia Colombo; Silvia Mola; Armando A Genazzani; Chiara Porta
Journal:  Pharmacol Res       Date:  2018-07-18       Impact factor: 7.658

2.  Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability.

Authors:  Hong Qiu; Anders Gabrielsen; Hanna E Agardh; Min Wan; Anders Wetterholm; Chi-Huey Wong; Ulf Hedin; Jesper Swedenborg; Göran K Hansson; Bengt Samuelsson; Gabrielle Paulsson-Berne; Jesper Z Haeggström
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-12       Impact factor: 11.205

Review 3.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

4.  Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease.

Authors:  Debby Ngo; Sumita Sinha; Dongxiao Shen; Eric W Kuhn; Michelle J Keyes; Xu Shi; Mark D Benson; John F O'Sullivan; Hasmik Keshishian; Laurie A Farrell; Michael A Fifer; Ramachandran S Vasan; Marc S Sabatine; Martin G Larson; Steven A Carr; Thomas J Wang; Robert E Gerszten
Journal:  Circulation       Date:  2016-07-26       Impact factor: 29.690

5.  Protective effects of matrix metalloproteinase-12 following corneal injury.

Authors:  Matilda F Chan; Jing Li; Anthony Bertrand; Amy-Jo Casbon; Jeffrey H Lin; Inna Maltseva; Zena Werb
Journal:  J Cell Sci       Date:  2013-06-26       Impact factor: 5.285

6.  Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy.

Authors:  Yuichi J Shimada; Kohei Hasegawa; Stephanie M Kochav; Pouya Mohajer; Jeeyoun Jung; Mathew S Maurer; Muredach P Reilly; Michael A Fifer
Journal:  J Cardiovasc Transl Res       Date:  2019-07-05       Impact factor: 4.132

7.  Aptamer-based multiplexed proteomic technology for biomarker discovery.

Authors:  Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N Brody; Jeff Carter; Andrew B Dalby; Bruce E Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R Keeney; Nancy Kim; Tad H Koch; Stephan Kraemer; Luke Kroiss; Ngan Le; Daniel Levine; Wes Lindsey; Bridget Lollo; Wes Mayfield; Mike Mehan; Robert Mehler; Sally K Nelson; Michele Nelson; Dan Nieuwlandt; Malti Nikrad; Urs Ochsner; Rachel M Ostroff; Matt Otis; Thomas Parker; Steve Pietrasiewicz; Daniel I Resnicow; John Rohloff; Glenn Sanders; Sarah Sattin; Daniel Schneider; Britta Singer; Martin Stanton; Alana Sterkel; Alex Stewart; Suzanne Stratford; Jonathan D Vaught; Mike Vrkljan; Jeffrey J Walker; Mike Watrobka; Sheela Waugh; Allison Weiss; Sheri K Wilcox; Alexey Wolfson; Steven K Wolk; Chi Zhang; Dom Zichi
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

8.  Causal analysis approaches in Ingenuity Pathway Analysis.

Authors:  Andreas Krämer; Jeff Green; Jack Pollard; Stuart Tugendreich
Journal:  Bioinformatics       Date:  2013-12-13       Impact factor: 6.937

9.  Correlations of MMP-1, MMP-3, and MMP-12 with the degree of atherosclerosis, plaque stability and cardiovascular and cerebrovascular events.

Authors:  Wei Hu; Rui Wei; Liyue Wang; Jingqian Lu; Hongming Liu; Wei Zhang
Journal:  Exp Ther Med       Date:  2017-12-12       Impact factor: 2.447

Review 10.  Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges.

Authors:  Nerea Méndez-Barbero; Carmen Gutiérrez-Muñoz; Rafael Blázquez-Serra; Jose L Martín-Ventura; Luis M Blanco-Colio
Journal:  Cells       Date:  2020-02-11       Impact factor: 6.600

View more
  4 in total

1.  Comprehensive Proteomics Profiling Identifies Patients With Late Gadolinium Enhancement on Cardiac Magnetic Resonance Imaging in the Hypertrophic Cardiomyopathy Population.

Authors:  Bradley S Lander; Yanling Zhao; Kohei Hasegawa; Mathew S Maurer; Albree Tower-Rader; Michael A Fifer; Muredach P Reilly; Yuichi J Shimada
Journal:  Front Cardiovasc Med       Date:  2022-06-17

2.  Plasma metabolomic profiling of hypertrophic cardiomyopathy patients before and after surgical myectomy suggests postoperative improvement in metabolic function.

Authors:  Nicole L Wolter; Madison J LeClair; Michael T Chin
Journal:  BMC Cardiovasc Disord       Date:  2021-12-28       Impact factor: 2.298

3.  Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy.

Authors:  Maike Schuldt; Beau van Driel; Sila Algül; Rahana Y Parbhudayal; Daniela Q C M Barge-Schaapveld; Ahmet Güçlü; Mark Jansen; Michelle Michels; Annette F Baas; Mark A van de Wiel; Max Nieuwdorp; Evgeni Levin; Tjeerd Germans; Judith J M Jans; Jolanda van der Velden
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

Review 4.  Recent Developments in Clinical Plasma Proteomics-Applied to Cardiovascular Research.

Authors:  Nicolai Bjødstrup Palstrøm; Rune Matthiesen; Lars Melholt Rasmussen; Hans Christian Beck
Journal:  Biomedicines       Date:  2022-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.